The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Targeted therapies in Pharmaceuticals: Photodynamic cancer therapy drugs.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Photodynamic cancer therapy drugs is a key innovation area in targeted therapies
Photodynamic therapy (PDT) is a class of therapy that uses light (photosensitising agent) to activate the drug (photosensitiser) to destroy cancer cells. PDT is highly precise and is used to target the cancer cells without affecting the normal cells. The drug is activated only on the cancer cells by using certain kinds of lasers,light-emitting diodes (LEDs), or radiation. It does not cause scarring, which makes it a good alternative to surgery.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of photodynamic cancer therapy drugs.
Key players in photodynamic cancer therapy drugs
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to photodynamic cancer therapy drugs
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Nanobiotix||191||Unlock company profile|
|PCI Biotech Holding||95||Unlock company profile|
|Vertex Pharmaceuticals||89||Unlock company profile|
|Merck & Co||73||Unlock company profile|
|MagForce||69||Unlock company profile|
|Rakuten Medical||62||Unlock company profile|
|Nanobacterie||58||Unlock company profile|
|Immunolight||51||Unlock company profile|
|Centre National de la Recherche Scientifique||42||Unlock company profile|
|Immunophotonics||41||Unlock company profile|
|Mayo Clinic||41||Unlock company profile|
|Aura Biosciences||39||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||37||Unlock company profile|
|MorEx Development Partners LLP||37||Unlock company profile|
|PT Soho Global Health Tbk||35||Unlock company profile|
|Lunella Biotech||32||Unlock company profile|
|Biolitec Unternehmensbeteiligungs II||32||Unlock company profile|
|Boston Scientific||31||Unlock company profile|
|MagForce Nanotechnologies||31||Unlock company profile|
|Rmw Cho Group||30||Unlock company profile|
|National Cancer Center||30||Unlock company profile|
|Luzitin||28||Unlock company profile|
|Biolitec Pharma Marketing||26||Unlock company profile|
|United States Of America||25||Unlock company profile|
|Health Research||25||Unlock company profile|
|Universidade de Coimbra||24||Unlock company profile|
|Agios Pharmaceuticals||23||Unlock company profile|
|Zhejiang Hisun Pharmaceutical||23||Unlock company profile|
|NH TherAguix||21||Unlock company profile|
|NewPhase||21||Unlock company profile|
|AbbVie||21||Unlock company profile|
|Diffusion Pharmaceuticals||20||Unlock company profile|
|Enovis||18||Unlock company profile|
|Endomagnetics||17||Unlock company profile|
|Massachusetts General Hospital||17||Unlock company profile|
|Commissariat a l'Energie et aux Energies Alternatives||17||Unlock company profile|
|CDH Investment Management Company||16||Unlock company profile|
|Calidi Biotherapeutics||16||Unlock company profile|
|Fumedica||16||Unlock company profile|
|Molteni Farmaceutici||16||Unlock company profile|
|SBI Holdings||16||Unlock company profile|
|Otsuka Holdings||16||Unlock company profile|
|Nanoquantum Sciences||15||Unlock company profile|
|Gilead Sciences||15||Unlock company profile|
|Antikor Biopharma||15||Unlock company profile|
|Soricimed Biopharma||14||Unlock company profile|
|On Target Laboratories||14||Unlock company profile|
|Siemens||14||Unlock company profile|
|International Research Council||13||Unlock company profile|
|DIATECH KOREA||13||Unlock company profile|
Source: GlobalData Patent Analytics
Nanobiotix is one of the leading patent filers in photodynamic cancer therapy drugs. The company is involved in designing and manufacturing nanoparticles that safely enhance radiation therapy's efficacy in cancer treatment. The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy..
In terms of application diversity, Merck is the top company, followed by GlycoMira Therapeutics and Vertex Pharmaceuticals. By means of geographic reach, Lunella Biotech holds the top position. Massachusetts General Hospital and Calidi Biotherapeutics are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.